170 results about "Thrombin" patented technology

The invention provides an anticoagulant coating for medical instruments, which can be used in the field of regenerative medical instruments. The prepared anticoagulant coating has short-term and long-term anticoagulant performance, and in addition, the thrombin responsive nanoparticles wrapped in the hydrogel coating can selectively release a factor Xa (FXa) inhibitor apixaban according to needs, so that thrombosis is inhibited in the middle stage of implantation. In-vitro and in-vivo experimental evidences show that after the material is implanted for a long time, an organized endodermis can be seen on the surface of the material, and the material has a special antithrombotic characteristic. The dynamic adjusting system has a multi-layer protection mechanism, and a new thought can be provided for designing the surface of a contact blood material adapting to environmental conditions.

The invention relates to the technical field of tumor biomedical engineering and organ chips, in particular to a vascularized gastric cancer organ chip and a preparation method thereof.The chip is composed of an integrated micro-fluidic main body, an annular micro-column array and an optical sealing film, and a central culture cavity is divided into a tumor area and a blood vessel area by micro-columns; the preparation method comprises the following steps: injecting a fibrous protein solution containing human umbilical vein endothelial cells and cancer-related fibroblasts into a vascular region, and adding thrombin for in-situ gelation to form a pre-vascularized network; the method comprises the following steps: mixing a patient-derived gastric cancer organ with a methacrylic acid esterified gelatin pre-polymerized solution, injecting the mixture into a tumor area, and carrying out photo-crosslinking immobilization; culturing for 7-14 days under the dynamic perfusion condition of a mixed culture medium to obtain a three-dimensional gastric cancer organ model containing a capillary network; the method is expected to be used for rapid, low-cost and high-throughput screening of chemotherapy or anti-angiogenesis drugs and accurate prediction of individual curative effects of patients.

The invention discloses a preparation method and application of autologous fibrin glue, and belongs to the field of biomedical materials. The preparation method comprises the following five steps: collecting autologous venous blood, adding a sodium citrate anticoagulant with the volume ratio of 1: (8-12), and storing at 4-6 DEG C for not more than 2 hours; performing step-by-step centrifugation at the speed of 1500 to 2000 r / min and the speed of 3500 to 4000 r / min to obtain a fibrinogen concentrate; the thrombin-calcium chloride activation solution A and the tranexamic acid activation solution B are mixed according to the ratio of 1: (2-3) to form a composite activation system; mixing the two components according to a mass ratio of 1: (0.8-1.2), and reacting at 25-37 DEG C for 3-5 minutes to form colloid; and pre-freezing at-40 to-60 DEG C, performing vacuum freeze-drying, and storing at 4-8 DEG C. During application, the colloid can be coated on an operation wound surface after being redissolved, or mixed with a growth factor to prepare a dressing for covering a chronic wound surface. The colloid is high in purity, stable in coagulation time, long in storage period, suitable for scenes such as surgical hemostasis and the like, and high in clinical value.

The invention relates to the technical field of biomedical materials, and discloses an antibacterial hemostatic material and a preparation method thereof, the antibacterial hemostatic material comprises the following components by weight: 2-3 parts of amino acid terminated polyurethane, 1-3 parts of thiolated chitosan, 3-5 parts of sodium alginate, and 2-4 parts of a polyvinyl alcohol solution. Through the synergistic effect of amino acid terminated polyurethane-sulfhydrylated chitosan-sodium alginate, a dual hemostatic mechanism of physical adsorption-chemical coagulation promotion is constructed: sodium alginate as a natural polysaccharide has strong hydrophilicity and cation adsorption capacity, can quickly absorb moisture in wound blood, concentrate platelets and coagulation factors, and has a good hemostatic effect; thrombin activation is accelerated, and the blood coagulation time is shortened; the antibacterial hemostatic material disclosed by the invention has relatively good antibacterial and hemostatic effects.

The invention provides autologous platelet-containing plasma gel and a preparation method and application thereof, and relates to the technical field of biological medicine and tissue engineering.The preparation method comprises the following steps that peripheral venous blood of a patient is extracted and added into a centrifugal tube mixed with a sodium citrate anticoagulant; putting the centrifugal tube into a centrifugal machine for centrifuging, and taking upper-layer plasma; wherein the upper-layer plasma refers to plasma between the upper-layer liquid level and the lower-layer red blood cell layer by 1mm; the centrifugal speed ranges from 1300 r / min to 1700 r / min; the centrifugation time is 3-5 min; under a sterile condition, preparing a calcium gluconate / thrombin mixed solution; and dropping the calcium gluconate / thrombin mixed solution into the upper plasma, mixing, and solidifying to obtain the autologous platelet-containing plasma gel. After one-time centrifugation, upper-layer full-layer plasma is extracted, the volume of the prepared gel is far larger than that of a traditional method, the utilization rate of whole blood platelets and fibrinogen is close to 100%, and regeneration and repair of large-area tissue wounds can be met.

The invention provides a wound hemostasis device for the emergency department, and relates to the technical field of wound hemostasis. The wound hemostasis device for the emergency department comprises an inflatable hemostasis air bag, and a constant-temperature film bag is fixedly connected to the lower surface of the inflatable hemostasis air bag. During working, a second infusion pump is started and pumps water in a constant-temperature water storage tank through a second infusion pipeline, the water enters a constant-temperature film bag through a fourth infusion pipeline, the temperature of a wound is guaranteed, meanwhile, a first infusion pump is started, a first water valve on a first infusion pipeline is opened, and a second water valve on a second infusion pipeline is opened. Water in the constant-temperature film bag is pumped through the first liquid pumping pipeline, and finally the water enters the constant-temperature water storage tank, so that the water in the constant-temperature film bag is always in a constant-temperature state, the temperature is ensured to be close to the optimum point of thrombin reaction, platelet aggregation and fibrin formation can be accelerated, and the method is safe and efficient, can minimize tissue damage, and is suitable for clinical application. And the hemostasis speed is accelerated.

The invention discloses a medicinal preparation for promoting healing of chronic diabetic wounds as well as a preparation method and application of the medicinal preparation, and relates to the technical field of medicinal preparations. According to the invention, a thrombin solution containing Se-CQDs and a fibrinogen solution containing GOX are mixed and reacted to prepare the pharmaceutical preparation for promoting healing of chronic wounds of diabetes. The pharmaceutical preparation for promoting healing of the chronic wound of diabetes can effectively remove excessive ROS at the chronic wound of diabetes and reduce the pH, glucose content and M1 / M2 macrophage proportion at the chronic wound, so that the high-glucose alkaline inflammation microenvironment of the chronic wound of diabetes is reversed, collagen deposition, revascularization and skin tissue reepithelization are promoted, and the healing of the chronic wound of diabetes is promoted. Therefore, healing of chronic diabetic wounds is promoted. Meanwhile, Se-CQDs and GOX are combined to prepare the pharmaceutical preparation, and the pharmaceutical preparation has a synergistic effect on promoting healing of chronic wounds of diabetes mellitus.

The invention discloses biological glue and a preparation method thereof.The preparation method comprises the steps that gel and activation liquid are prepared, and the gel is prepared by evenly mixing I-type collagen freeze-dried powder, chitosan and a fibrinogen solution; and mixing the freeze-dried thrombin with a calcium chloride solution to prepare an activation solution. The meninx suturing device has the advantages that sliding in the meninx suturing process is effectively reduced, an operation is easier to carry out, the risk that the meninx or a repairing material slides after the operation can be reduced, and a wound is evenly healed; most of the components are type I collagen which is beneficial to meninx injury repair, and the components contain chitosan which has antibacterial and hemostatic effects.

The invention discloses a PRP (platelet-rich plasma) stem cell exosome chitosan composition as well as a preparation method and application thereof. The PRP stem cell exosome chitosan composition comprises the following components: activated platelet-rich plasma, stem cell exosome and chitosan. The preparation method of the composite gel comprises the following steps: adding chitosan into a suspension containing activated platelet-rich plasma and stem cell exosome, uniformly mixing, adding a povidone suspending aid, oscillating to form a stable suspension state, adjusting the pH value to 7.5-7.8, mixing with thrombin and a calcium agent, stirring in a dark place, and solidifying to form a gelatinous substance, thereby obtaining the composite gel. The platelet-rich plasma-stem cell exosome-chitosan composite gel is obtained. The composition and the composite gel can promote microvascular endothelial cell regeneration and recover normal vascular endothelial morphology and functions; skin regeneration is promoted; broad-spectrum bacteriostasis and lipid reduction are realized, and local inflammation and immune response are inhibited.

The invention belongs to the field of biomedical materials, and particularly relates to a coagulation-promoting embolism microsphere and a preparation method thereof. The sericin-based embolism microspheres are creatively prepared, and the sericin membrane layer on the surface of the microspheres can prevent the risk that a catheter is solidified during an operation due to thrombin burst release during the operation. On the other hand, sericin in the microspheres has excellent water absorption swelling property and lubricity, and is beneficial to embolism and prevention of reflux; moreover, sericin molecules contain a large amount of hydroxyl and carboxyl, so that the chelation of blood coagulation factor calcium ions is greatly improved. In addition, thrombin factors are loaded into the microspheres, calcium ions are chelated on the surfaces of the microspheres, the microspheres are endowed with rapid embolism capacity through the superimposed effect, blood flow blocking of target blood vessels can be effectively accelerated, and reflux is prevented. The prepared procoagulant embolism microspheres are suitable for being applied to treatment of vascular-rich tumors of the brain and can effectively prevent mistaken closure of many complex functional blood vessels of the brain due to reflux.

Disclosed are a fibrinogen solution and a thrombin solution. The fibrinogen solution comprises fibrinogen at a concentration of at least 40 mg / ml, factor XIII, pharmaceutically acceptable additives and water. The dynamic viscosity of the fibrinogen solution measured at 20° C. increases at most by 35% after storing the solution at 20° C. for 30 days. The thrombin solution comprises thrombin, pharmaceutically acceptable additives and water.

The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof.

The invention discloses a nucleic acid aptamer with enhanced affinity after cyclic hybridization as well as a screening method and application thereof, relates to the technical field of nucleic acid aptamer screening, and successfully develops a CH-SELEX method by taking human alpha-thrombin as a research object on the basis of compatibility with MB-SELEX under the condition of introducing cyclic hybridization. Through multiple rounds of positive screening under the condition of introducing cyclic hybridization and negative screening under the condition of adding His-small peptide modified magnetic beads and human serum, the nucleic acid aptamer which can specifically recognize human alpha-thrombin and has obviously improved affinity after cyclic hybridization is screened; and the affinity of the nucleic acid aptamer can be regulated and controlled by increasing the length of the hybrid complementary chain, so that reference is provided for diagnosis and treatment of diseases related to human alpha-thrombin and development of sensors, concept verification and methodological reference is provided for regulation and control of other important biological processes, and the blank of the method is filled.

The application relates to the technical field of medical dressing preparation, and discloses a hemostatic, healing-promoting and antibacterial foam dressing and a preparation method thereof. The method uses sodium alginate and carboxymethyl chitosan as a composite polysaccharide matrix, mixes the two, adds a calcium chloride solution to crosslink a porous gel support, and then carries out freeze-drying to obtain a porous framework; gelatin and polyvinyl alcohol can be further added to enhance the mechanical strength, zeolite particles loaded with silver ions are added to achieve antibacterial performance, epidermal growth factor release microspheres are added to promote healing, and the dressing can be further subjected to heparinization, plasma surface modification, thrombin addition, salt precipitation pore formation and sterilization treatment. The dressing prepared by the method has the functions of synergistic hemostasis, antibiosis and healing promotion, has good biocompatibility and suitable mechanical strength, and has a simple preparation process, and can be used for various wound care.

The invention relates to the technical field of biological medicine, and discloses a platelet-rich plasma exosome gel preparation method, which comprises: carrying out exosome separation on a PRP sample by using a high-speed centrifuge; stuffing the exosome precipitate into the shell-sphere structure to prepare core-shell structure particles so as to coat the exosome and form a thermal insulation layer; mixing thrombin and calcium gluconate according to a mass ratio of 10: 1, and adding the mixture into PRP to prepare a gel matrix; adding a photoinitiator, the magnetic coloring particles and the core-shell structure particles into the gel matrix, and uniformly mixing to prepare exosome gel; the invention further discloses application of the composition in repairing diabetic foot wounds. According to the invention, the irreversible influence of temporary environment change on the system can be weakened, meanwhile, the double mechanisms of healing are disclosed, during application, secondary arrangement is carried out by using a magnetic field, the release efficiency of PRP-Exo is improved under the later photo-thermal cooperation effect, and accurate formulation of a long-term treatment strategy is facilitated.

The invention relates to oil seal liquid and application thereof in blood coagulation detection, and belongs to the technical field of blood coagulation detection. The oil seal liquid can form a uniform film when covering a plasma sample, the activity of thrombin is not affected while air is isolated, and in addition, the oil seal liquid is a biological inert formula, is easy to clean and does not generate adsorption or reaction with blood coagulation factors and reagents. Therefore, the oil seal liquid and the sample are incubated synchronously in the pre-warming stage, and errors caused by sample evaporation and temperature fluctuation in the pre-warming stage can be reduced. Compared with traditional paraffin oil, the oil seal liquid can effectively isolate air to avoid sample evaporation and reduce reagent interference, is easy to clean, provides reliable technical support for blood coagulation factor deficiency and precise identification of inhibitors, and is suitable for APTT correction experiments, PT correction experiments or clinical detection and application of lupus anticoagulant (LA).

The invention relates to a kit capable of detecting different types of targets based on DNA multi-pass knots and a detection method. The kit comprises a detection composition and a test strip, the detection composition comprises a molecular beacon and an auxiliary chain, wherein the nucleotide sequence of the molecular beacon (MB) is as shown in SEQ ID No.1; the auxiliary chain is a combination of HBV-alpha1 and HBV-beta1, and / or a combination of miR-21-alpha2 and miR-21-beta2, and / or a combination of ATP-alpha3 and ATP-beta3, and / or a combination of Thrombin-alpha4 and Thrombin-beta4, and / or a combination of TdT-alpha5 and TdT-beta5, and the sequence of the auxiliary chain is as shown in SEQ ID No.2-11. The kit can detect different types of targets, and when a target exists, no matter DNA / RNA, small molecules, proteins or enzymes, alpha and beta auxiliary chains can be connected together and hybridized with MB to form a DNA multi-pass node, so that a test line develops color, the target is conveniently and intuitively determined, and the detection time is shortened. Remodification of nano-particles, re-pretreatment of a pad / film and assembly and cutting of test paper are avoided, and a large amount of manpower, material resources and financial resources are saved.

The invention provides special gel for medical surgical site ice compress and a preparation method thereof, and relates to the technical field of medical treatment. The preparation raw materials at least comprise: a main polymer: polyvinyl alcohol (PVA), bacterial nanocellulose (BNC), and poly N-isopropylacrylamide; the functional additives comprise double modified starch (OSA + phosphate), nano-silver (the particle size is 20-50 nm), a thrombin-fibrinogen compound and EGF / bFGF microspheres (PLGA); and the auxiliary components comprise glycerol, citric acid and purified water. According to the multifunctional ice compress gel, a structure which is loose outside and tight inside is formed through freeze drying, the cold compress uniformity and the air circulation performance are improved, the double modified starch and the cross-linking agent cooperate, the degradation period is prolonged to 72 h, the replacement frequency is reduced, the multifunctional ice compress gel has the functions of physical cooling, hemostasis repair, antisepsis and anti-inflammation, the cooperative requirement of postoperative cold compress and wound surface nursing is met, and the multifunctional ice compress gel is worthy of popularization and application. The device is suitable for postoperative incision cold compress, burn / acute stage cooling and hemostasis of wounds and auxiliary repair of chronic wounds.

The application relates to the technical field of medicines, and discloses application of gymnemon and a medicine thereof.According to the application, the gymnemon can be used for preparing medicines related to cardiovascular diseases, including medicines for improving heart failure, inhibiting myocardial hypertrophy, improving vascular endothelial function and reducing blood pressure, and further used for preparing medicines for reducing expressions of vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 and / or increasing serum NO level; the gymnemon can also be used for preparing medicines for regulating abnormal lipid metabolism, including medicines for reducing triglyceride and total cholesterol level; the gymnemon can also be used for preparing medicines for relieving liver injury, including medicines for reducing glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase level; and the gymnemon can also be used for preparing medicines for improving systemic inflammation and / or platelet and thrombin dysfunction.

The present application relates to a method for preparing and expanding a TSCM cell in vitro. Specifically, the method comprises: 1) obtaining an isolated CD8+ T cell; 2) activating the CD8+ T cell; 3) mixing the activated CD8+ T cell, a fibrinogen solution and a thrombin solution, and culturing same under conditions suitable for cell growth, so as to obtain a TSCM cell culture; and 4) bringing the culture into contact with a dispase so as to obtain a TSCM cell. The present application also relates to a kit for preparing and expanding a TSCM cell in vitro, the use of fibrinogen and thrombin in the preparation of a kit for preparing and expanding a TSCM cell in vitro, and a TSCM cell obtained by means of the method or kit of the present application.

The invention belongs to the technical field of biomedical material engineering, and discloses a hydrogel scaffold used for 3D tumor sphere culture and drug screening, the scaffold is formed by four-arm polyethylene glycol maleimide, fibrinogen and thrombin through Michael addition crosslinking and biopolymerization synergistically, the elastic modulus of 10-1000 Pa can be adjusted by regulating and controlling the proportion of all the components, and the hydrogel scaffold can be used for 3D tumor sphere culture and drug screening. Gel forming is completed within 5 min at the room temperature. The scaffold has the biological activity of fibrous protein and the structural stability of polyethylene glycol, can efficiently support HCT116 cells to form high-activity tumor balls, accurately simulate the in-vivo tumor microenvironment and remarkably improve the accuracy and repeatability of drug screening, is easy and convenient to operate, is compatible with a standard pore plate high-throughput platform and is suitable for drug sensitivity detection of personalized treatment of tumors.

Provided herein are novel compounds of Formula I, or a pharmaceutically acceptable salt thereof or pharmaceutical compositions including the same. Also provided are methods of preparing the compounds of Formula I, or pharmaceutically acceptable salt thereof. Further provided are methods of using the novel compounds of Formula I, or a pharmaceutically acceptable salt thereof, for example, for inhibiting thrombin and / or for the use in the prevention and / or treatment of thrombin-mediated and thrombin-related diseases.

The utility model provides a thrombin determination kit fixing frame convenient to expand, which relates to the technical field of medical instruments and comprises a fixing base. A fixing frame is inserted into the top end face of the fixing base, a partition plate is slidably connected into the fixing frame, a control rod is rotatably connected to the middle of the top end face of the partition plate, walking gears are symmetrically and rotatably connected to the left and right sides of the upper and lower end faces of the partition plate, and a locking pin is slidably connected into the partition plate in the middle of the top of the control rod. According to the thrombin determination kit fixing frame convenient to expand, the fixing frames are rapidly spliced through the connecting combination blocks, the connecting combination grooves and the butterfly nuts at the top and the connecting lug blocks and the connecting lug grooves at the bottom, a user can conveniently and rapidly expand the scale of the fixing frame according to actual requirements, and it is ensured that the overall structure is stable; therefore, the problems that a fixing frame is fixed in structure, single in mounting position, difficult to adapt to quantity change, low in space utilization rate and difficult to flexibly adjust a partition plate are solved.

The application belongs to the technical field of biotechnology, and particularly relates to a kind of snake venom polypeptide and application thereof.The snake venom polypeptide is polypeptide DACU-1, polypeptide DACU-2 or polypeptide DACU-3.The application provides a kind of new snake venom polypeptide, including three polypeptides, and the three polypeptides all have anti-platelet aggregation activity, and have the activity of inhibiting platelet aggregation under the stimulation of ADP, arachidonic acid, collagen, thrombin and other various activators, and have the potential to be developed into anti-platelet drugs, functional foods and health products.

The invention relates to the technical field of in-vitro diagnosis, in particular to a lupus anticoagulant detection kit based on recombinant snake venom enzyme and application of the lupus anticoagulant detection kit. The probe comprises a recombinant snake venom thrombin-like enzyme, a phospholipid-quantum dot conjugate, calcium ions, sodium citrate, trehalose, polyethylene glycol, L-histidine, EDTA-2Na, a Tris-HCl buffer solution, a nanogold-carbon nanotube composite probe, a graphene oxide-chitosan composite material, a fluorescence enhancer and a stabilizer. The kit disclosed by the invention is high in detection sensitivity, strong in matrix interference resistance, excellent in recombinant snake venom enzyme stability and good in batch-to-batch consistency, the detection specificity can be accurately verified, and the problem that the performance of a traditional kit is poor is solved.

The present invention relates to a pharmaceutical composition and a health functional food for the prevention or treatment of thrombosis containing an extract of *Barbarea orthoceras Ledeb*, and more specifically, to a pharmaceutical composition and a health functional food for the prevention or treatment / improvement of thrombosis through inhibition of blood coagulation containing, as an active ingredient, a hot water extract of the whole plant of *Barbarea orthoceras Ledeb* having potent thrombin inhibitory and blood coagulation factor inhibitory activities. The extract of *Barbarea orthoceras* (Ledeb) as an active ingredient in the pharmaceutical composition and health functional food for the prevention or treatment of thrombosis according to the present invention exhibits excellent antithrombotic activity through strong inhibition of thrombus-related enzymes such as thrombin and blood coagulation factors. At the same time, it does not exhibit any hemolytic activity against human red blood cells, has excellent thermal stability, and does not show loss of blood coagulation factor inhibitory effects or thrombus-related enzyme inhibitory effects even under acidic conditions of pH 2 and in plasma. Therefore, it is expected to be usable for the prevention and treatment of thrombosis, such as ischemic stroke and hemorrhagic stroke, through the improvement of blood circulation. Furthermore, since the active ingredient has the excellent effect of being processed into various forms such as extract, powder, pills, and tablets, allowing for formulation into a form suitable for regular consumption, this invention is highly useful for the pharmaceutical and food industries.

The invention discloses a 5 / 8 / 5 chitosan clostridium diterpenoid compound, a biosynthetic gene cluster and application of the biosynthetic gene cluster, and relates to the technical field of biological medicines. A 5 / 8 / 5 chitin type diterpenoid biosynthetic gene cluster Thm in trichoderma harzianum is identified through a genome mining system, chitin diterpenoid compounds with diversified structures are obtained by means of heterologous expression, the obtained compounds are subjected to anti-thrombotic activity comprehensive evaluation, and the result shows that the compounds 6 and 31 can obviously inhibit vascular thrombosis, the compound 6 has a remarkable inhibition effect on collagen-induced platelet aggregation, and the compound 31 has a better inhibition capability on thrombin-induced platelet activation. The compounds 6 and 31 show powerful antithrombotic effects in artery, vein and pulmonary artery thrombosis models, so that powerful technical support is provided for development of antithrombotic drugs.

The present disclosure relates to hemostatic compositions comprising a biocompatible polymer, thrombin, and hemofibrinogen, and methods for preparing such compositions.

The present invention relates to a polypeptide derived from natural tridegin by structural modification, which may serve as an inhibitor of plasma coagulation factor XIIIa, and to pharmaceutical compositions comprising such polypeptide. The present invention further refers to such polypeptide or pharmaceutical composition for use in a method for treating or preventing a thrombotic event in a patient. Moreover, the invention relates to an endoprosthesis or an enzyme-linked immunosorbent assay (ELISA) plate coated with a polypeptide of the present invention. Furthermore, the invention also encompasses a recombinant fusion protein comprising this polypeptide linked to a fibrinolytic enzyme such as streptokinase, nattokinase or tPAs via a flexible peptide linker containing a thrombin-cleavable site. This construct allows selective inhibition of FXIIIa within a thrombus, while enabling thrombin-triggered release of the fibrinolytic enzyme to induce localized fibrinolysis, thereby achieving targeted dual-action thrombolytic therapy.

The present invention belongs to the fields of polypeptide synthesis and biomedicine technology, and specifically relates to a polypeptide PM7 and its application in preventing and treating thrombosis. The present invention obtains an original polypeptide from the transcriptome of the salivary gland of the leech Philippine cattle leech, and truncates the original polypeptide to bind to the fibrinogen binding site of thrombin, thereby interfering with the activity of thrombin. Furthermore, {d-Phe}-PRP is added to the N-terminus of the truncated polypeptide, and {d-Phe}-PRP and the truncated polypeptide are connected with a connecting polypeptide to obtain the polypeptide PM7. The polypeptide PM7 of the present invention has the activity of inhibiting thrombin, has a shorter half-life in the body, and is highly safe, thereby achieving the effect of preventing and treating thrombosis.